 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > AVAX Technologies, Inc.
 |
AVAX Technologies, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
AVAX Technologies Q2 loss matches year-ago Aug 07 2001 08:59 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
AVAX Technologies believes a cure for cancer could be a vaccine away. The development-stage biotech company concentrates on cancer treatments. AC Vaccine, its leading technology, calls for a patient's cancer cells, harvested from tumors, to be modified and used to fight the cancer. The company's lead product candidate is M-Vax, a treatment for melanoma (skin cancer). It is also developing O-Vax to treat ovarian cancer. The firm is working to gain approval for its vaccine technology in Australia, Europe, Japan, and the US. AVAX does not engage in pure research, instead licensing the underlying technology from research institutions, including those at Rutgers University and Texas A&M University.
COMPETITION |
 |
Antigenics Inc. (AGEN)
Biomira Inc. (BIOM)
Progenics Pharmaceuticals, Inc. (PGNX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (92.5)%
KEY PEOPLE |
 |
David L. Tousley
CEO
David L. Tousley
CFO
CONTACT INFO |
 |
4520 Main St., Ste. 930
Kansas City, MO 64111
US
Phone: 816-960-1333
Fax: 816-960-1334
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |